Drug Search Results
More Filters [+]

Mirdametinib

Alternative Names: mirdametinib, pd 0325901, pd-0325901, pd0325901
Latest Update: 2024-02-15
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: PI3K Inhibitor,mTOR

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: SpringWorks Therapeutics
Company Location: STAMFORD CT 06902
Company CEO: Saqib Islam
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Mirdametinib

Countries in Clinic: Australia, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 2: Glioma|Neurofibroma, Plexiform|Neurofibromatoses|Neurofibromatosis 1|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SJ901

P2

Recruiting

Glioma

2031-06-01

MEKRAF-AST-101

P2

Recruiting

Oncology Solid Tumor Unspecified

2026-10-31

57%

MEKRAF-AST-101

P2

Recruiting

Oncology Solid Tumor Unspecified

2026-10-31

57%

BGB-283/PD-0325901-AU-001

P1

Recruiting

Oncology Solid Tumor Unspecified

2025-09-30

50%

BGB-283/PD-0325901-AU-001

P1

Recruiting

Oncology Solid Tumor Unspecified

2025-09-30

50%

ReNeu

P2

Active, not recruiting

Neurofibromatosis 1|Neurofibromatoses|Neurofibroma, Plexiform

2023-09-20

57%

Recent News Events